Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Syndax Pharmaceuticals
SNDX
Syndax Pharmaceuticals
Regulatory And Pricing Risks Will Curb Prospects Yet Kindle Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
07 Aug 25
Updated
10 Aug 25
2
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$17.00
13.4% undervalued
intrinsic discount
10 Aug
US$14.73
Loading
1Y
-26.2%
7D
15.8%
Author's Valuation
US$17.0
13.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$17.0
13.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-391m
441m
2014
2017
2020
2023
2025
2026
2028
Revenue US$441.0m
Earnings US$62.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
36.93%
Biotech revenue growth rate
12.85%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.11%
Calculation
US$62.28m
Earnings '28
x
29.87x
PE Ratio '28
=
US$1.86b
Market Cap '28
US$1.86b
Market Cap '28
/
89.36m
No. shares '28
=
US$20.82
Share Price '28
US$20.82
Share Price '28
Discounted to 2025 @ 7.13% p.a.
=
US$16.93
Fair Value '25